


ImmunityBio Platforms

Immunotherapy 2.0: Cytokines + Vaccine + Cellular Therapy Platforms

Fusion Proteins



NK & T Cell Activator
Memory T Cell

ANKTIVA


In-Vivo Lymphocyte Rescue

NMIBC CIS

US FDA Approved 2024
UK MHRA Approved 2026
EU EMA Approved 2025

NMIBC CIS & NSCLC
Saudi FDA Approved 2026

DNA Vaccine



Adenovirus (hAd5)

hAd5 CEA, MUC1, Brachyury

hAd5 PSA

hAd5 HPV

In-Vivo Lymphocyte Education

Phase 2

Cellular Therapy

CAR-NK



Off-The-Shelf
CAR-NK


PD-L1 t-haNK

CD19 t-haNK

Ex-Vivo Lymphocyte Rescue

Phase 2

Apheresis



Ex-Vivo Cytokine Proliferation

M-ceNK

Ex-Vivo Lymphocyte Rescue

Phase 2

NASDAQ:IBRX - A Comprehensive Immunotherapy Company with Platforms
Orchestrating Natural Killer, CD4+, CD8+ Killer T Cells and Memory T Cells for Durable
Complete Responses Across Multiple Tumor Types